Alzheimer's prevention testing made simple

Early detection

We are pioneering the use of emerging proteomic technologies to understand your future brain health, now. We offer a one-of-a-kind pairing of best-in-class clinical biomarker analysis with active respiratory and viral infection testing to detect Alzheimer’s neurodegeneration in its earliest stages.

Personalized insights

We utilize CNS and inflammatory proteomics, comprehensive genetic profiling—including transcriptomic, epigenetic, and mitochondrial analyses—and lifestyle assessments to develop individualized models of disease progression. This approach allows us to generate personalized health strategies that empower patients to understand their disease risk and effectively mitigate it.

Cutting Edge Research

Our research focuses on illuminating rare, neglected, or currently incurable diseases of the central nervous system. We target conditions such as preclinical Alzheimer’s disease, ME/CFS, Batten Disease, and Parkinson’s disease. Additionally, we collaborate with global experts on post-acute sequelae of COVID-19 (long-COVID) to better understand its role in neurodegeneration. Our goal is to determine how viral infections increase the risk of developing dementia and to provide patients with effective strategies to mitigate that risk.